Alisporivir
An antiviral cyclic peptide.
General information
Alisporivir is a cyclic peptide investigated for its antiviral properties (ChEBI).
Alisporivir on DrugBank
Alisporivir on PubChem
Alisporivir on Wikipedia
Synonyms
Debio-025
CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Small molecule In vitro Screening |
Huh7.5 cells; Calu-3 cells; primary normal human bronchial epithelial cells; iPSC-derived AT2 cells; SARS-CoV-2 strain USA WA1/2020 | 8.11 | Inhibited SARS-CoV-2 replication in Huh7.5 cells, Calu-3 cells, or primary normal human bronchial epithelial cells. |
Mar/23/2021 |
AI-suggested references
Clinical trials
ID | Title | Status | Phase | Start date | Completion date |
---|---|---|---|---|---|
NCT04608214 | Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19) | Not yet recruiting | Phase 2 | Nov/01/2020 | Aug/04/2021 |
|